AXSM
Axsome Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
174.59
▼ 2.49 (1.41%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
177.01
Prev close
177.08
Day high
176.52
Day low
169.31
Volume
1.37M
Market cap
$9.13B
P/E (TTM)
—
52W range
117.30 – 260.19
Day trading desk
Gap from prior close
-0.04%
Prior close 177.08
VWAP
173.75
+0.48% from price
Relative volume
1.28×
Normal
Session range
5.14%
169.31 – 178.00
Position in range
61%
Mid range
ATR (14D)
7.22
4.13% of price
Prior day high
179.70
PDH
Prior day low
175.73
PDL
Bid / ask spread
—
Quote not published
Session volume
887.09K
Avg 692.86K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.34%
-8.3%
1M
-15.65%
-16.8%
3M
-29.01%
-33.5%
6M
+3.32%
-14.9%
YTD
-4.54%
-18.8%
1Y
+44.92%
+28.5%
3Y
+149.45%
+67.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AXSM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-13.64K
Net selling
Buy transactions
11
209.97K shares
Sell transactions
11
223.60K shares
Net transactions
+22
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
7.90M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 3, 26 | JACOBSON MARK L Chief Operating Officer |
SELL | 10.00K | $2.09M | Direct |
| Sep 3, 26 | JACOBSON MARK L Chief Operating Officer |
CONVERSION | 10.00K | $129.50K | Direct |
| Aug 6, 26 | TABUTEAU HERRIOT Chief Executive Officer |
SELL | 49.66K | $10.54M | Direct |
| Aug 6, 26 | TABUTEAU HERRIOT Chief Executive Officer |
CONVERSION | 49.66K | $245.84K | Direct |
| Jul 1, 26 | TABUTEAU HERRIOT Chief Executive Officer |
SELL | 49.67K | $11.93M | Direct |
| Jul 1, 26 | TABUTEAU HERRIOT Chief Executive Officer |
CONVERSION | 49.67K | $11.93M | Direct |
| Jun 11, 26 | JEFFS ROGER A Director |
SELL | 572 | $141.66K | Direct |
| Jun 10, 26 | COLEMAN MARK H Director |
SELL | 643 | $160.11K | Direct |
| Jun 10, 26 | MAHONY SUSAN M Director |
SELL | 600 | $145.02K | Direct |
| Jun 9, 26 | TABUTEAU HERRIOT Chief Executive Officer |
SELL | 49.67K | $11.97M | Direct |
| Jun 9, 26 | TABUTEAU HERRIOT Chief Executive Officer |
CONVERSION | 49.67K | $245.87K | Direct |
| Jun 9, 26 | PIZZIE NICK Chief Financial Officer |
SELL | 33.00K | $7.92M | Direct |
| Jun 9, 26 | PIZZIE NICK Chief Financial Officer |
CONVERSION | 33.00K | $115.50K | Direct |
| Jun 8, 26 | JEFFS ROGER A Director |
— | 1.43K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COLEMAN MARK H |
Director | 434.25K | Sale |
JACOBSON MARK L |
Chief Operating Officer | 0 | Sale |
JEFFS ROGER A |
Director | 58.37K | Sale |
MAHONY SUSAN M |
Director | 829 | Sale |
MAIZEL ARI |
Officer | 0 | Sale |
MURDOCK HUNTER R |
General Counsel | 0 | Sale |
PIZZIE NICK |
Chief Financial Officer | 43.35K | Sale |
SAAD MARK E |
Director | 11.73K | Conversion of Exercise of derivative security |
TABUTEAU HERRIOT |
Chief Executive Officer | 7.35M | Sale |
Fundamentals
Market cap$9.13B
Enterprise value$9.04B
Revenue (TTM)$776.57M
Gross profit$724.04M
EBITDA$-172.92M
Net income$-191.64M
EPS (TTM)$-3.68
Free cash flow$-4.58M
Total cash$319.85M
Total debt$224.69M
Book value / share$1.59
Shares outstanding52.38M
Float44.46M
Short % of float9.29%
Dividend yield0.00%
Beta (5Y)0.85
Valuation & profitability ratios
Trailing P/E—
Forward P/E36.95
PEG ratio—
Price / sales—
Price / book109.44
EV / revenue11.64
EV / EBITDA-52.26
Gross margin93.24%
Operating margin-23.42%
Profit margin-24.68%
Return on equity-245.10%
Return on assets-16.31%
Debt / equity269.73
Current ratio1.43
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $638.50M | $385.69M | $270.60M | $50.04M | +65.5% |
| Operating revenue | $638.50M | $385.69M | $270.60M | $50.04M | +65.5% |
| Cost of revenue | $47.48M | $33.30M | $26.07M | $5.20M | +42.6% |
| Gross profit | $591.02M | $352.39M | $244.53M | $44.84M | +67.7% |
| Research & development | $183.28M | $187.08M | $97.94M | $57.95M | -2.0% |
| Selling, general & admin | $570.60M | $411.36M | $323.12M | $159.25M | +38.7% |
| Total operating expense | $760.25M | $604.83M | $427.44M | $221.34M | +25.7% |
| Operating income | -$169.24M | -$252.44M | -$182.91M | -$176.50M | +33.0% |
| Net interest income | -$6.56M | -$6.57M | -$6.45M | -$7.33M | +0.2% |
| Pre-tax income | -$183.70M | -$287.13M | -$238.28M | -$187.13M | +36.0% |
| Tax provision | -$530.00K | $85.00K | $960.00K | $0 | -723.5% |
| Net income | -$183.17M | -$287.22M | -$239.24M | -$187.13M | +36.2% |
| Net income to common | -$183.17M | -$287.22M | -$239.24M | -$187.13M | +36.2% |
| Basic EPS | -3.68 | -5.99 | -5.27 | -4.60 | +38.6% |
| Diluted EPS | -3.68 | -5.99 | -5.27 | -4.60 | +38.6% |
| EBIT | -$177.15M | -$280.56M | -$231.82M | -$179.80M | +36.9% |
| EBITDA | -$168.08M | -$272.60M | -$224.99M | -$175.40M | +38.3% |
| Basic shares | 49.75M | 47.91M | 45.43M | 40.66M | +3.8% |
| Diluted shares | 49.75M | 47.91M | 45.43M | 40.66M | +3.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $322.93M | $315.35M | $386.19M | $200.84M | +2.4% |
| Cash & short-term investments | $322.93M | $315.35M | $386.19M | $200.84M | +2.4% |
| Accounts receivable | $224.46M | $142.00M | $94.82M | $37.70M | +58.1% |
| Inventory | $27.94M | $15.73M | $15.13M | $4.32M | +77.6% |
| Total current assets | $588.99M | $485.06M | $504.26M | $245.64M | +21.4% |
| Property, plant & equipment | $21.42M | $5.97M | $7.62M | $1.14M | +259.0% |
| Goodwill & intangibles | $52.56M | $58.94M | $65.33M | $69.97M | -10.8% |
| Total assets | $689.80M | $568.50M | $588.24M | $331.48M | +21.3% |
| Total current liabilities | $378.84M | $230.10M | $138.85M | $96.56M | +64.6% |
| Current debt | $70.00M | — | — | — | — |
| Long-term debt | $117.75M | $180.71M | $178.07M | $94.26M | -34.8% |
| Total debt | $218.11M | $192.96M | $186.37M | $94.68M | +13.0% |
| Total liabilities | $601.51M | $511.48M | $397.26M | $221.92M | +17.6% |
| Retained earnings | -$1.31B | -$1.12B | -$835.57M | -$596.33M | -16.3% |
| Shareholder equity | $88.30M | $57.02M | $190.98M | $109.56M | +54.9% |
| Working capital | $210.15M | $254.96M | $365.41M | $149.08M | -17.6% |
| Net tangible assets | $35.73M | -$1.92M | $125.65M | $39.59M | +1,960.2% |
| Shares issued | 50.88M | 48.67M | 47.35M | 43.50M | +4.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$183.17M | -$287.22M | -$239.24M | -$187.13M | +36.2% |
| Depreciation & amortisation | $9.06M | $7.96M | $6.83M | $4.40M | +13.9% |
| Stock-based compensation | $93.75M | $85.22M | $62.62M | $37.73M | +10.0% |
| Change in working capital | -$22.52M | $33.90M | -$28.39M | $23.67M | -166.4% |
| Operating cash flow | -$93.41M | -$128.41M | -$145.08M | -$116.51M | +27.3% |
| Capital expenditure | -$480.00K | -$270.00K | -$582.00K | -$702.00K | -77.8% |
| Investing cash flow | -$480.00K | -$270.00K | -$582.00K | -$53.70M | -77.8% |
| Financing cash flow | $101.47M | $57.84M | $331.01M | $284.58M | +75.4% |
| Free cash flow | -$93.89M | -$128.68M | -$145.66M | -$117.21M | +27.0% |
| End cash position | $322.93M | $315.35M | $386.19M | $200.84M | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $218.38M | $191.20M | $196.00M | $170.99M | $150.04M | +14.2% |
| Operating revenue | $218.38M | $191.20M | $196.00M | $170.99M | $150.04M | +14.2% |
| Cost of revenue | $13.56M | $14.72M | $12.33M | $11.91M | $13.45M | -7.9% |
| Gross profit | $204.81M | $176.48M | $183.67M | $159.08M | $136.59M | +16.1% |
| Research & development | $46.23M | $52.68M | $48.79M | $40.16M | $49.54M | -12.2% |
| Selling, general & admin | $208.14M | $185.00M | $169.30M | $150.24M | $130.28M | +12.5% |
| Total operating expense | $255.95M | $239.25M | $219.69M | $192.00M | $181.41M | +7.0% |
| Operating income | -$51.14M | -$62.77M | -$36.02M | -$32.92M | -$44.82M | +18.5% |
| Net interest income | -$1.54M | -$1.19M | -$1.17M | -$1.12M | -$1.83M | -30.0% |
| Pre-tax income | -$51.19M | -$64.54M | -$28.13M | -$47.23M | -$48.93M | +20.7% |
| Tax provision | $128.00K | $0 | $430.00K | $0 | -$960.00K | — |
| Net income | -$51.31M | -$64.54M | -$28.56M | -$47.23M | -$47.97M | +20.5% |
| Net income to common | -$51.31M | -$64.54M | -$28.56M | -$47.23M | -$47.97M | +20.5% |
| Basic EPS | -0.99 | -1.26 | -0.56 | -0.94 | -0.97 | +21.4% |
| Diluted EPS | -0.99 | -1.26 | -0.56 | -0.94 | -0.97 | +21.4% |
| EBIT | -$49.65M | -$63.36M | -$26.96M | -$46.11M | -$47.10M | +21.6% |
| EBITDA | -$46.76M | -$60.99M | -$24.68M | -$43.70M | -$44.85M | +23.3% |
| Basic shares | 51.80M | 51.20M | 50.63M | 50.02M | 49.44M | +1.2% |
| Diluted shares | 51.80M | 51.20M | 50.63M | 50.02M | 49.44M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $319.85M | $305.11M | $322.93M | $325.27M | $303.02M | +4.8% |
| Cash & short-term investments | $319.85M | $305.11M | $322.93M | $325.27M | $303.02M | +4.8% |
| Accounts receivable | $277.46M | $251.06M | $224.46M | $196.51M | $198.82M | +10.5% |
| Inventory | $37.88M | $31.52M | $27.94M | $23.77M | $18.44M | +20.2% |
| Total current assets | $656.57M | $611.21M | $588.99M | $565.34M | $536.62M | +7.4% |
| Property, plant & equipment | $20.03M | $20.58M | $21.42M | $22.26M | $23.14M | -2.7% |
| Goodwill & intangibles | $49.40M | $50.99M | $52.56M | $54.17M | $55.77M | -3.1% |
| Total assets | $761.45M | $713.61M | $689.80M | $669.25M | $639.78M | +6.7% |
| Total current liabilities | $460.45M | $439.21M | $378.84M | $360.29M | $342.10M | +4.8% |
| Current debt | $70.00M | $70.00M | $70.00M | $70.00M | $70.00M | 0.0% |
| Long-term debt | $117.96M | $117.85M | $117.75M | $117.64M | $117.54M | +0.1% |
| Total debt | $224.69M | $219.90M | $218.11M | $218.60M | $217.31M | +2.2% |
| Total liabilities | $678.14M | $659.02M | $601.51M | $595.52M | $566.71M | +2.9% |
| Retained earnings | -$1.42B | -$1.37B | -$1.31B | -$1.28B | -$1.23B | -3.7% |
| Shareholder equity | $83.30M | $54.59M | $88.30M | $73.73M | $73.08M | +52.6% |
| Working capital | $196.12M | $172.00M | $210.15M | $205.05M | $194.52M | +14.0% |
| Net tangible assets | $33.90M | $3.60M | $35.73M | $19.56M | $17.30M | +842.3% |
| Shares issued | 52.30M | 51.42M | 50.88M | 50.31M | 49.82M | +1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$51.31M | -$64.54M | -$28.56M | -$47.23M | -$47.97M | +20.5% |
| Depreciation & amortisation | $2.89M | $2.37M | $2.27M | $2.41M | $2.25M | +22.0% |
| Stock-based compensation | $27.15M | $23.44M | $22.73M | $23.10M | $24.61M | +15.8% |
| Change in working capital | -$10.41M | $17.05M | -$6.83M | $8.78M | -$14.33M | -161.0% |
| Operating cash flow | -$32.95M | -$20.70M | -$18.65M | $1.05M | -$32.42M | -59.2% |
| Capital expenditure | -$450.00K | -$121.00K | -$71.00K | -$58.00K | -$13.00K | -271.9% |
| Investing cash flow | -$450.00K | -$121.00K | -$71.00K | -$58.00K | -$13.00K | -271.9% |
| Financing cash flow | $48.15M | $2.99M | $16.39M | $21.27M | $34.54M | +1,508.1% |
| Free cash flow | -$33.40M | -$20.82M | -$18.72M | $988.00K | -$32.44M | -60.4% |
| End cash position | $319.85M | $305.11M | $322.93M | $325.27M | $303.02M | +4.8% |
Options analytics
Put / call volume
0.68
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
135.00
-22.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
310
Contracts, this expiry
Put volume
211
Contracts, this expiry
Heaviest call OI
135.00
0 contracts
Heaviest put OI
155.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.78 | -0.99 | -26.9% |
| Mar 2026 | -0.86 | -1.26 | -46.0% |
| Dec 2025 | -0.73 | -0.56 | +23.6% |
| Sep 2025 | -0.90 | -0.94 | -4.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.50 | 12 | $256.73M | +50.1% |
| Next quarter | 0.05 | 12 | $296.97M | +51.5% |
| Current year | -2.69 | 12 | $963.34M | +50.9% |
| Next year | 4.72 | 12 | $1.55B | +60.6% |
Analyst targets & ownership
Mean target$284.63
High target$380.00
Low target$246.00
Implied upside63.03%
Analyst count22
ConsensusSTRONG BUY
Strong buy / Buy3 / 18
Hold1
Sell / Strong sell0 / 0
Held by insiders15.08%
Held by institutions74.59%
Institutions holding661
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
186.17
-6.22% from price
SMA 20
198.37
-12.12% from price
SMA 50
206.85
-15.72% from price
SMA 100
222.72
-21.61% from price
SMA 200
200.07
-12.86% from price
EMA 12
187.63
-6.95% from price
EMA 26
196.71
-11.24% from price
EMA 50
205.09
-14.87% from price
RSI (14)
25.9
Oversold
MACD (12,26,9)
-9.08
Hist -2.42
ATR (14)
7.22
4.14% of price
Realised vol 30D
37.0%
Annualised
Bollinger upper
226.11
20, 2σ
Bollinger lower
170.64
20, 2σ
50 / 200 cross
Golden
206.85 vs 200.07
Trend bias
Below 200
-12.86%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.60
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
37.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.7%
Peak to trough
Max drawdown 5Y
-53.5%
Peak to trough
ATR 14
7.22
4.14% of price
Beta (reported)
0.85
5Y monthly, from filing
Short interest
Shares short
3.14M
Prior 3.21M
Change vs prior
-2.1%
Shorts covering
% of float
9.29%
Normal
% of shares out
5.99%
Against total outstanding
Days to cover
5.5
Crowded exit
Float
44.46M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| Sep 25, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Sep 23, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Sep 18, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 11, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 11, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 31, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-03
Periodic Financial Reports
10-Q · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-30
Annual Report to Shareholders
ARS · 2026-04-24
Corporate Changes & Voting Matters
8-K · 2026-04-01
Headlines
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)
Insider Monkey · 2d ago
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Motley Fool · 5d ago
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com · 6d ago
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating
MT Newswires · 8d ago
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating
MT Newswires · 14d ago
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
GlobeNewswire · 16d ago
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
MarketBeat · 17d ago
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues
Simply Wall St. · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.